Pulmatrix, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 78/100
What the filing says
On March 26, 2026, Pulmatrix entered into a merger agreement with Eos SENOLYTIX (a privately held gerotherapeutics company) anticipated to close Q3 2026. Simultaneously, Pulmatrix raised $1.0M gross proceeds via private placement of Series B Convertible Preferred Stock to an Eos affiliate. The company has paused all clinical development and now seeks to out-license or monetize three clinical assets: PUR1900 (antifungal, 2% royalties to Cipla outside US; 50/50 US rights), PUR3100 (migraine treatment, Phase 2 IND accepted), and PUR1800 (COPD treatment, Phase 1b complete). Cash declined from $4.1M (Dec 31, 2025) to $2.2M (June 30, 2026); company states cash is sufficient through merger closing.
Why this rating
Merger with smaller private biotech is material relative to Pulmatrix's $25M market cap. Pipeline deprioritization and pivot to out-licensing/monetization signals major strategic shift. $1M raise is 4% of market cap but modest. Going-concern language and cash burn warrant attention, but merger timing and operational adjustments mitigate urgency. Neither transformational nor routine.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.